Open AccessEffectiveness and safety of switching to adalimumab biosimilar ABP 501 in Crohn�s disease.
Author(s) -
Angelo Viscido,
Giovanni Latella
Publication year - 2020
Publication title -
revista española de enfermedades digestivas/revista española de enfermedades digestivas
Language(s) - English
Resource type - Journals
eISSN - 2340-4167
pISSN - 1130-0108
DOI - 10.17235/reed.2020.7232/2020
Subject(s) - biosimilar , medicine , adalimumab , crohn's disease , disease
We read with great interest the article "Effectiveness and safety of adalimumab biosimilar ABP 501 in Crohn's disease: an observational study" by Ribaldone et al., which was recently published in your journal. The authors report the first real-life study of the adalimumab biosimilar ABP 501 in Crohn's disease (CD). The study investigated the short-term effectiveness and safety of ABP 501 in 87 patients with CD, 25 patients naïve to adalimumab and 62 switched from the adalimumab originator. A meaningful proportion of CD patients treated with ABP 501 showed clinical benefit with a satisfactory safety profile until the end of follow-up.